MAX and MYC: a heritable breakup.

The overexpression of MYC, which occurs in many tumors, dramatically disrupts the equilibrium between activation and repression of the oncogenic MYC/MYC-associated protein X (MAX)/MAX dimerization protein 1 (MXD1) network, favoring MYC-MAX complexes and thereby impairing differentiation and promoting cell growth. Although for some time it has appeared that MAX is necessary for both the activation and repression of the axis, recent evidence shows that MYC retains considerable biologic function in the absence of MAX. The presence of germline MAX mutations in patients with hereditary pheochromocytoma supports the predominant role of MAX as a negative regulator of the network and suggests that MYC deregulation plays a role in hereditary cancer predisposition. This finding also confirms the importance of impairment of the MYC/MAX/MXD1 axis in the development of aggressive neural tumors, because MYCN overexpression is an established genetic hallmark of malign neuroblastoma, and it is likely that MXI1 plays a relevant role in the development of medulloblastoma and glioblastoma. Finally, the likely malignant behavior of tumors with mutations in MAX points to MYC as a candidate therapeutic target in the treatment of metastatic pheochromocytoma.

[1]  A. Saltiel,et al.  c-Myc Does Not Require Max for Transcriptional Activity in PC-12 Cells , 1994, Molecular and Cellular Neuroscience.

[2]  P. Hurlin,et al.  The MAX-interacting transcription factor network. , 2006, Seminars in cancer biology.

[3]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[4]  A. Look,et al.  Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis. , 2009, Cancer research.

[5]  N. Cheung,et al.  The MYCN enigma: significance of MYCN expression in neuroblastoma. , 2006, Cancer research.

[6]  Joseph R. Bertino.  Encyclopedia of cancer , 2002 .

[7]  C. Johannessen,et al.  The NF1 tumor suppressor critically regulates TSC2 and mTOR. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Patricia L. M. Dahia,et al.  Germline mutations in TMEM127 confer susceptibility to pheochromocytoma , 2010, Nature Genetics.

[9]  Ken Chen,et al.  Gene-target recognition among members of the Myc superfamily and implications for oncogenesis , 2000, Nature Genetics.

[10]  D. Boger,et al.  Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Alt,et al.  Transposition and amplification of oncogene-related sequences in human neuroblastomas , 1983, Cell.

[12]  R. DePinho,et al.  Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth , 1998, Nature.

[13]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[14]  T. Matise,et al.  Loss of heterozygosity for chromosome 14q in neuroblastoma. , 2001, Medical and pediatric oncology.

[15]  P. Leder,et al.  Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor , 1983, Cell.

[16]  J. Blenis,et al.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Hosoi,et al.  Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN , 2003, International journal of cancer.

[18]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[19]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[20]  B. Job,et al.  Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma , 2011, British Journal of Cancer.

[21]  David M. Livingston,et al.  A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G0 Cells , 2002, Science.

[22]  Agnieszka Maliszewska,et al.  Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. , 2010, Molecular endocrinology.

[23]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[24]  J. Tonn,et al.  Analysis of the max‐binding protein MNT in human medulloblastomas , 1999, International journal of cancer.

[25]  A. González-Neira,et al.  Genetics of pheochromocytoma and paraganglioma in Spanish patients. , 2009, The Journal of clinical endocrinology and metabolism.

[26]  Hans van Bokhoven,et al.  MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome , 2005, Nature Genetics.

[27]  E. Passegué,et al.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch , 2006, Proceedings of the National Academy of Sciences.

[28]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[29]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[30]  J. Bishop,et al.  Negative Control of the Myc Protein by the Stress-Responsive Kinase Pak2 , 2004, Molecular and Cellular Biology.

[31]  Arthur R. Brothman,et al.  Mutation of the MXI1 gene in prostate cancer , 1995, Nature Genetics.

[32]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[33]  P. Gallant,et al.  Myc’s secret life without Max , 2009, Cell cycle.

[34]  D. Wechsler,et al.  MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. , 1997, Cancer research.

[35]  M. Billaud,et al.  Transforming Ability of MEN2A-RET Requires Activation of the Phosphatidylinositol 3-Kinase/AKT Signaling Pathway* , 2000, The Journal of Biological Chemistry.

[36]  A. Wynshaw-Boris,et al.  Inflammatory Disease and Lymphomagenesis Caused by Deletion of the Myc Antagonist Mnt in T Cells , 2006, Molecular and Cellular Biology.

[37]  E. Korpershoek,et al.  Conditional Pten knock‐out mice: a model for metastatic phaeochromocytoma , 2009, The Journal of pathology.

[38]  J. Blenis,et al.  Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1 , 2008, Proceedings of the National Academy of Sciences.

[39]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[40]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[41]  J. Benítez,et al.  Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma , 2011, Nature Genetics.

[42]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[43]  D. Wechsler,et al.  MXI 1 , a Putative Tumor Suppressor Gene , Suppresses Growth of Human Glioblastoma Cells 1 , 2006 .